As the durability and predictive power of resectable xenograft models has previously been shown in the neoadjuvant22 and metastatic setting23, we employed Her2+ breast cancer xenografts to accurately recapitulate the clinical adjuvant disease setting. This evidence concerns the gene ERBB2 and breast carcinoma.